Utomilumab |
PF-05082566; PF-2566; PF-5082566 |
Phase 3 Clinical |
Pfizer Inc |
Prostatic Neoplasms, Castration-Resistant; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Oropharyngeal Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Solid tumours; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Head and Neck Neoplasms; Lymphoma, B-Cell; Ovarian Neoplasms |
Details
|
Urelumab |
BMS-66513; BMS-663513 |
Phase 2 Clinical |
Bristol-Myers Squibb Company |
Multiple Myeloma; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Leukemia, B-Cell; Gliosarcoma; Colorectal Neoplasms; Brain Neoplasms; Urinary Bladder Neoplasms; Lymphoma, B-Cell; Carcinoma, Transitional Cell; Skin Neoplasms; Neoplasms; Glioblastoma; Solid tumours; Leukemia; Head and Neck Neoplasms |
Details
|
ALG.APV-527 |
ALG-APV-527; ADC-1016; ATOR-1016; ALG.APV-527 |
Phase 2 Clinical |
Aptevo, Alligator Bioscience Ab |
Solid tumours; Neoplasms |
Details
|
PE-0116 |
PE-0116 |
Phase 2 Clinical |
Shanghai HyaMab Biotech Co Ltd |
Solid tumours |
Details
|
Delolimogene mupadenorepvec |
LOAd-703 |
Phase 2 Clinical |
Uppsala University, Lokon Pharma |
Biliary Tract Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma |
Details
|
ADG-106 |
ADG-106 |
Phase 2 Clinical |
Adagene (Suzhou) Ltd |
Solid tumours; Lymphoma, Non-Hodgkin |
Details
|
Cinrebafusp alfa |
PRS-343 |
Phase 2 Clinical |
Pieris Pharmaceuticals |
Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms |
Details
|
Enristomig |
ES101; INBRX-105 |
Phase 2 Clinical |
Inhibrx |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Thoracic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Nasopharyngeal Carcinoma; Oropharyngeal Neoplasms; Esophageal adenocarcinoma; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Tecaginlimab |
BNT-312; GEN-1042 |
Phase 2 Clinical |
Genmab A/S |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Peripheral Nervous System Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
AP-203 |
AP-203; AP203 |
Phase 2 Clinical |
AP Biosciences Inc |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
BOS-342 |
PRS-342; BOS-342; PRS-342/BOS-342 |
Phase 2 Clinical |
Pieris Pharmaceuticals |
Solid tumours; Carcinoma, Hepatocellular |
Details
|
YH-32367 |
ABL105; YH-32367 |
Phase 2 Clinical |
Abl Bio Inc |
Solid tumours; Stomach Neoplasms; Breast Neoplasms |
Details
|
BT-7480 |
BT-7480 |
Phase 2 Clinical |
Bicycle Therapeutics |
Solid tumours; Neoplasms |
Details
|
Acasunlimab |
PD-L1x4-1BB; DuoBody-PD-L1x4-1BB; GEN1046; BNT-311 |
Phase 2 Clinical |
Genmab A/S, Biontech Se |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
Exlinkibart |
LVGN-6051 |
Phase 2 Clinical |
Lyvgen Biopharma(HK)Ltd |
Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Papillomavirus Infections; Neoplasms; Uveal melanoma; Sarcoma; Carcinoma, Hepatocellular; Neoplasm Metastasis |
Details
|
DSP-107 |
DSP-107; KAHR-107 |
Phase 2 Clinical |
Kahr Medical |
Solid tumours; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung |
Details
|
DuoBody-EpCAMx4-1BB |
BNT314/GEN1059; GEN-1059; GEN1059; BNT314 |
Phase 2 Clinical |
Biontech Se, Genmab A/S |
Solid tumours; Neoplasms |
Details
|
LM-24C5 |
LM-24C5 |
Phase 2 Clinical |
LaNova Medicines Ltd |
Solid tumours; Neoplasms |
Details
|
IBD-0333 |
IBD-0333; IBD0333 |
Phase 2 Clinical |
SunHo (China) BioPharmaceutical Co Ltd |
Solid tumours; Neoplasms; Lymphoma, Non-Hodgkin |
Details
|
PRS-344 |
PRS-344/ONC0055; PRS-344; PRS-344/S095012; PRS-344S095012; S-095012 |
Phase 2 Clinical |
Pieris Pharmaceuticals Inc, Laboratoires Servier |
Solid tumours |
Details
|
Emfizatamab |
GNC-038 |
Phase 2 Clinical |
SystImmune |
Solid tumours; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Central Nervous System Lymphoma |
Details
|
Humanized CART Directed Against BCMA |
ARI-0002h |
Phase 2 Clinical |
Instituto De Salud Carlos Iii |
Multiple Myeloma |
Details
|
PM-1032 |
PM1032; PM-1032 |
Phase 2 Clinical |
Biotheus Inc, Shanghai Genechem Co Ltd |
Neoplasms |
Details
|
LBL-024 |
LBL-024; LBL024 |
Phase 2 Clinical |
Nanjing Leads Biolabs Co Ltd |
Solid tumours; Neoplasms; Carcinoma, Neuroendocrine |
Details
|
QLF31907 |
QLF31907; QLF-31907 |
Phase 2 Clinical |
Qilu Pharmaceutical Co Ltd |
Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Lymphoma, Non-Hodgkin; Melanoma |
Details
|
EU-101 |
EU-101; NOV-1801 |
Phase 2 Clinical |
Eutilex |
Solid tumours; Carcinoma, Renal Cell; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Nebratamig |
GNC-035 |
Phase 2 Clinical |
|
Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Metastatic breast cancer; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
RO-7122290 |
RO-7122290; RG-7827 |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Colorectal Neoplasms |
Details
|
PM-1003 |
PM1003 |
Phase 2 Clinical |
Biotheus Inc |
Solid tumours |
Details
|
FS-120 |
FS-120 |
Phase 1 Clinical |
F-Star |
Neoplasms; Neoplasm Metastasis |
Details
|
MCLA-145 |
MCLA-145 |
Phase 1 Clinical |
Incyte Corp, Merus Nv |
Solid tumours; Lymphoma, B-Cell; Neoplasms |
Details
|
AGEN-2373 |
AGEN-2373 |
Phase 1 Clinical |
Agenus Inc |
Neoplasms |
Details
|
CTX-471 |
CTX-471 |
Phase 1 Clinical |
Compass Therapeutics LLC |
Head and Neck Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Mesothelioma; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
Details
|
ABL-103 |
ABL-103 |
Phase 1 Clinical |
Abl Bio Inc, Handok Inc |
Solid tumours |
Details
|
BH-3120 |
BH-3120 |
Phase 1 Clinical |
Hanmi Pharmaceutical Co Ltd |
Solid tumours |
Details
|
Xirestomig |
ATG-101; ATG101; YN051 |
Phase 1 Clinical |
The Origin Cell Technology Group Co Ltd |
Solid tumours; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neoplasm Metastasis |
Details
|
QL-301 |
QL-301 |
Phase 1 Clinical |
Qlsf Biotherapeutics Inc |
Neoplasms |
Details
|
MP-0310 |
MP-0310; AMG-506 |
Phase 1 Clinical |
Molecular Partners Ag, Amgen Inc |
Solid tumours |
Details
|
ND-021 |
ND-021; NM21-1480; CS-2006; CS2006 |
Phase 1 Clinical |
Numab Therapeutics Ag, Cstone Pharmaceuticals |
Solid tumours; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
FTL-008.16 |
FTL-008.16; FTL008.16 |
Phase 1 Clinical |
Sound(Chengdu)Biopharmacauticals Co Ltd |
Solid tumours |
Details
|
NBL-028 |
NBL028; NBL-028 |
Phase 1 Clinical |
Shanghai Xinshi Biological Medicine Co Ltd, Novarock Biotherapeutics Ltd |
Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Neoplasms; Testicular Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
BC 3425 |
BC-3425 |
Phase 1 Clinical |
|
Solid tumours |
Details
|
89Zr-S095012 |
89Zr-S-095012 |
Phase 1 Clinical |
Institut De Recherches Internationales Servier |
Solid tumours |
Details
|
SGN-BB228 |
SGN-BB228 |
Phase 1 Clinical |
|
Skin Melanoma; Pancreatic Neoplasms; Mesothelioma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
HK-010 |
HK-010; HK010 |
Phase 1 Clinical |
Anhui Anke Biotechnology (Group) Co Ltd, Hefei Hankemab Biotechnology Co Ltd |
Neoplasms |
Details
|
Ori-Bs-001 |
Ori-Bs-001 |
Phase 1 Clinical |
OriCell Therapeutics Co Ltd |
Solid tumours |
Details
|
CART-38(University of Pennsylvania) |
CART-38 |
Phase 1 Clinical |
University Of Pennsylvania |
Multiple Myeloma; Leukemia, Myeloid, Acute |
Details
|
IMB-071703 |
IMB-071703; IMB071703 |
Phase 1 Clinical |
Beijng Immunoah Pharma Tech Co Ltd |
Solid tumours |
Details
|
ADG-206 |
ADG-206 |
Phase 1 Clinical |
Adagene (Suzhou) Ltd |
Neoplasms |
Details
|
ZG-033 |
ZG033 |
Phase 1 Clinical |
Hefei Hankemab Biotechnology Co Ltd |
Neoplasms |
Details
|
STA-551 |
STA-551 |
Phase 1 Clinical |
Chugai Pharmaceutical Co Ltd |
Solid tumours |
Details
|
Englumafusp alfa |
RG-6076; RO-7227166 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Lymphoma, Non-Hodgkin |
Details
|
FS-222 |
FS-222 |
Phase 1 Clinical |
F-star Beta Ltd |
Neoplasms; Neoplasm Metastasis |
Details
|
FTL-001 |
FTL001; FTL-001 |
Phase 1 Clinical |
Xikang (Wuhan) Biomedicine Co Ltd, Sound(Chengdu)Biopharmacauticals Co Ltd |
Solid tumours |
Details
|
Sytalizumab |
TWP-101 |
Phase 1 Clinical |
Therawisdom Biopharma Co Ltd |
Solid tumours; Carcinoma, Transitional Cell; Melanoma |
Details
|
DF-003(Dingfu Biotarget) |
DF-003 |
Phase 1 Clinical |
Dingfu Biotarget Co Ltd |
Solid tumours; Lymphoma, Non-Hodgkin |
Details
|
CB-307 |
CB-307 |
Phase 1 Clinical |
Crescendo Bioscience Inc |
Neoplasms |
Details
|
Givastomig |
TJ-CD4B; ABL-111; TJ-CLDN4B; TJ-033721; TJ-CD4B/ABL111 |
Phase 1 Clinical |
I-Mab Biopharma Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Esophageal adenocarcinoma; Neoplasm Metastasis |
Details
|
TJ-L14B |
ABL-503; TJ-L14B/ABL503; ABL503 |
Phase 1 Clinical |
I-Mab Biopharma Co Ltd |
Solid tumours |
Details
|
HLX-35 |
HLX-35 |
Phase 1 Clinical |
Shanghai Henlius Biologics Co Ltd |
Solid tumours; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
GNC-039 |
GNC-039 |
Phase 1 Clinical |
|
Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis |
Details
|
HBM-7008 |
HBM7008; HBM-7008; R-7008 |
Phase 1 Clinical |
Harbour Biomed |
Solid tumours |
Details
|
IBI-319 |
IBI-319 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Neoplasms |
Details
|
YH-004 |
YH-004 |
Phase 1 Clinical |
Eucure Pharmaceutical Technology (Beijing) Co Ltd |
Solid tumours; Neoplasms; Lymphoma, Non-Hodgkin |
Details
|
HOT-1030 |
HOT-1030 |
Phase 1 Clinical |
|
Solid tumours |
Details
|
QL-1806 |
QL-1806 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Neoplasms |
Details
|
Cedarizumab |
|
Phase 1 Clinical |
Therawisdom Biopharma Co Ltd |
Solid tumours; Carcinoma, Transitional Cell; Melanoma |
Details
|
Evunzekibart |
ATOR-1017 |
Phase 1 Clinical |
Alligator Bioscience Ab |
Solid tumours; Neoplasms |
Details
|
Utomilumab |
PF-05082566; PF-2566; PF-5082566 |
Phase 3 Clinical |
Pfizer Inc |
Prostatic Neoplasms, Castration-Resistant; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Oropharyngeal Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Solid tumours; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Head and Neck Neoplasms; Lymphoma, B-Cell; Ovarian Neoplasms |
Details
|
Urelumab |
BMS-66513; BMS-663513 |
Phase 2 Clinical |
Bristol-Myers Squibb Company |
Multiple Myeloma; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Leukemia, B-Cell; Gliosarcoma; Colorectal Neoplasms; Brain Neoplasms; Urinary Bladder Neoplasms; Lymphoma, B-Cell; Carcinoma, Transitional Cell; Skin Neoplasms; Neoplasms; Glioblastoma; Solid tumours; Leukemia; Head and Neck Neoplasms |
Details
|
ALG.APV-527 |
ALG-APV-527; ADC-1016; ATOR-1016; ALG.APV-527 |
Phase 2 Clinical |
Aptevo, Alligator Bioscience Ab |
Solid tumours; Neoplasms |
Details
|
PE-0116 |
PE-0116 |
Phase 2 Clinical |
Shanghai HyaMab Biotech Co Ltd |
Solid tumours |
Details
|
Delolimogene mupadenorepvec |
LOAd-703 |
Phase 2 Clinical |
Uppsala University, Lokon Pharma |
Biliary Tract Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma |
Details
|
ADG-106 |
ADG-106 |
Phase 2 Clinical |
Adagene (Suzhou) Ltd |
Solid tumours; Lymphoma, Non-Hodgkin |
Details
|
Cinrebafusp alfa |
PRS-343 |
Phase 2 Clinical |
Pieris Pharmaceuticals |
Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms |
Details
|
Enristomig |
ES101; INBRX-105 |
Phase 2 Clinical |
Inhibrx |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Thoracic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Nasopharyngeal Carcinoma; Oropharyngeal Neoplasms; Esophageal adenocarcinoma; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Tecaginlimab |
BNT-312; GEN-1042 |
Phase 2 Clinical |
Genmab A/S |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Peripheral Nervous System Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
AP-203 |
AP-203; AP203 |
Phase 2 Clinical |
AP Biosciences Inc |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
BOS-342 |
PRS-342; BOS-342; PRS-342/BOS-342 |
Phase 2 Clinical |
Pieris Pharmaceuticals |
Solid tumours; Carcinoma, Hepatocellular |
Details
|
YH-32367 |
ABL105; YH-32367 |
Phase 2 Clinical |
Abl Bio Inc |
Solid tumours; Stomach Neoplasms; Breast Neoplasms |
Details
|
BT-7480 |
BT-7480 |
Phase 2 Clinical |
Bicycle Therapeutics |
Solid tumours; Neoplasms |
Details
|
Acasunlimab |
PD-L1x4-1BB; DuoBody-PD-L1x4-1BB; GEN1046; BNT-311 |
Phase 2 Clinical |
Genmab A/S, Biontech Se |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
Exlinkibart |
LVGN-6051 |
Phase 2 Clinical |
Lyvgen Biopharma(HK)Ltd |
Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Papillomavirus Infections; Neoplasms; Uveal melanoma; Sarcoma; Carcinoma, Hepatocellular; Neoplasm Metastasis |
Details
|
DSP-107 |
DSP-107; KAHR-107 |
Phase 2 Clinical |
Kahr Medical |
Solid tumours; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung |
Details
|
DuoBody-EpCAMx4-1BB |
BNT314/GEN1059; GEN-1059; GEN1059; BNT314 |
Phase 2 Clinical |
Biontech Se, Genmab A/S |
Solid tumours; Neoplasms |
Details
|
LM-24C5 |
LM-24C5 |
Phase 2 Clinical |
LaNova Medicines Ltd |
Solid tumours; Neoplasms |
Details
|
IBD-0333 |
IBD-0333; IBD0333 |
Phase 2 Clinical |
SunHo (China) BioPharmaceutical Co Ltd |
Solid tumours; Neoplasms; Lymphoma, Non-Hodgkin |
Details
|
PRS-344 |
PRS-344/ONC0055; PRS-344; PRS-344/S095012; PRS-344S095012; S-095012 |
Phase 2 Clinical |
Pieris Pharmaceuticals Inc, Laboratoires Servier |
Solid tumours |
Details
|
Emfizatamab |
GNC-038 |
Phase 2 Clinical |
SystImmune |
Solid tumours; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Central Nervous System Lymphoma |
Details
|
Humanized CART Directed Against BCMA |
ARI-0002h |
Phase 2 Clinical |
Instituto De Salud Carlos Iii |
Multiple Myeloma |
Details
|
PM-1032 |
PM1032; PM-1032 |
Phase 2 Clinical |
Biotheus Inc, Shanghai Genechem Co Ltd |
Neoplasms |
Details
|
LBL-024 |
LBL-024; LBL024 |
Phase 2 Clinical |
Nanjing Leads Biolabs Co Ltd |
Solid tumours; Neoplasms; Carcinoma, Neuroendocrine |
Details
|
QLF31907 |
QLF31907; QLF-31907 |
Phase 2 Clinical |
Qilu Pharmaceutical Co Ltd |
Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Lymphoma, Non-Hodgkin; Melanoma |
Details
|
EU-101 |
EU-101; NOV-1801 |
Phase 2 Clinical |
Eutilex |
Solid tumours; Carcinoma, Renal Cell; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Nebratamig |
GNC-035 |
Phase 2 Clinical |
|
Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Metastatic breast cancer; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
RO-7122290 |
RO-7122290; RG-7827 |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Colorectal Neoplasms |
Details
|
PM-1003 |
PM1003 |
Phase 2 Clinical |
Biotheus Inc |
Solid tumours |
Details
|
FS-120 |
FS-120 |
Phase 1 Clinical |
F-Star |
Neoplasms; Neoplasm Metastasis |
Details
|
MCLA-145 |
MCLA-145 |
Phase 1 Clinical |
Incyte Corp, Merus Nv |
Solid tumours; Lymphoma, B-Cell; Neoplasms |
Details
|
AGEN-2373 |
AGEN-2373 |
Phase 1 Clinical |
Agenus Inc |
Neoplasms |
Details
|
CTX-471 |
CTX-471 |
Phase 1 Clinical |
Compass Therapeutics LLC |
Head and Neck Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Mesothelioma; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
Details
|
ABL-103 |
ABL-103 |
Phase 1 Clinical |
Abl Bio Inc, Handok Inc |
Solid tumours |
Details
|
BH-3120 |
BH-3120 |
Phase 1 Clinical |
Hanmi Pharmaceutical Co Ltd |
Solid tumours |
Details
|
Xirestomig |
ATG-101; ATG101; YN051 |
Phase 1 Clinical |
The Origin Cell Technology Group Co Ltd |
Solid tumours; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neoplasm Metastasis |
Details
|
QL-301 |
QL-301 |
Phase 1 Clinical |
Qlsf Biotherapeutics Inc |
Neoplasms |
Details
|
MP-0310 |
MP-0310; AMG-506 |
Phase 1 Clinical |
Molecular Partners Ag, Amgen Inc |
Solid tumours |
Details
|
ND-021 |
ND-021; NM21-1480; CS-2006; CS2006 |
Phase 1 Clinical |
Numab Therapeutics Ag, Cstone Pharmaceuticals |
Solid tumours; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
FTL-008.16 |
FTL-008.16; FTL008.16 |
Phase 1 Clinical |
Sound(Chengdu)Biopharmacauticals Co Ltd |
Solid tumours |
Details
|
NBL-028 |
NBL028; NBL-028 |
Phase 1 Clinical |
Shanghai Xinshi Biological Medicine Co Ltd, Novarock Biotherapeutics Ltd |
Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Neoplasms; Testicular Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
BC 3425 |
BC-3425 |
Phase 1 Clinical |
|
Solid tumours |
Details
|
89Zr-S095012 |
89Zr-S-095012 |
Phase 1 Clinical |
Institut De Recherches Internationales Servier |
Solid tumours |
Details
|
SGN-BB228 |
SGN-BB228 |
Phase 1 Clinical |
|
Skin Melanoma; Pancreatic Neoplasms; Mesothelioma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
HK-010 |
HK-010; HK010 |
Phase 1 Clinical |
Anhui Anke Biotechnology (Group) Co Ltd, Hefei Hankemab Biotechnology Co Ltd |
Neoplasms |
Details
|
Ori-Bs-001 |
Ori-Bs-001 |
Phase 1 Clinical |
OriCell Therapeutics Co Ltd |
Solid tumours |
Details
|
CART-38(University of Pennsylvania) |
CART-38 |
Phase 1 Clinical |
University Of Pennsylvania |
Multiple Myeloma; Leukemia, Myeloid, Acute |
Details
|
IMB-071703 |
IMB-071703; IMB071703 |
Phase 1 Clinical |
Beijng Immunoah Pharma Tech Co Ltd |
Solid tumours |
Details
|
ADG-206 |
ADG-206 |
Phase 1 Clinical |
Adagene (Suzhou) Ltd |
Neoplasms |
Details
|
ZG-033 |
ZG033 |
Phase 1 Clinical |
Hefei Hankemab Biotechnology Co Ltd |
Neoplasms |
Details
|
STA-551 |
STA-551 |
Phase 1 Clinical |
Chugai Pharmaceutical Co Ltd |
Solid tumours |
Details
|
Englumafusp alfa |
RG-6076; RO-7227166 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Lymphoma, Non-Hodgkin |
Details
|
FS-222 |
FS-222 |
Phase 1 Clinical |
F-star Beta Ltd |
Neoplasms; Neoplasm Metastasis |
Details
|
FTL-001 |
FTL001; FTL-001 |
Phase 1 Clinical |
Xikang (Wuhan) Biomedicine Co Ltd, Sound(Chengdu)Biopharmacauticals Co Ltd |
Solid tumours |
Details
|
Sytalizumab |
TWP-101 |
Phase 1 Clinical |
Therawisdom Biopharma Co Ltd |
Solid tumours; Carcinoma, Transitional Cell; Melanoma |
Details
|
DF-003(Dingfu Biotarget) |
DF-003 |
Phase 1 Clinical |
Dingfu Biotarget Co Ltd |
Solid tumours; Lymphoma, Non-Hodgkin |
Details
|
CB-307 |
CB-307 |
Phase 1 Clinical |
Crescendo Bioscience Inc |
Neoplasms |
Details
|
Givastomig |
TJ-CD4B; ABL-111; TJ-CLDN4B; TJ-033721; TJ-CD4B/ABL111 |
Phase 1 Clinical |
I-Mab Biopharma Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Esophageal adenocarcinoma; Neoplasm Metastasis |
Details
|
TJ-L14B |
ABL-503; TJ-L14B/ABL503; ABL503 |
Phase 1 Clinical |
I-Mab Biopharma Co Ltd |
Solid tumours |
Details
|
HLX-35 |
HLX-35 |
Phase 1 Clinical |
Shanghai Henlius Biologics Co Ltd |
Solid tumours; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
GNC-039 |
GNC-039 |
Phase 1 Clinical |
|
Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis |
Details
|
HBM-7008 |
HBM7008; HBM-7008; R-7008 |
Phase 1 Clinical |
Harbour Biomed |
Solid tumours |
Details
|
IBI-319 |
IBI-319 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Neoplasms |
Details
|
YH-004 |
YH-004 |
Phase 1 Clinical |
Eucure Pharmaceutical Technology (Beijing) Co Ltd |
Solid tumours; Neoplasms; Lymphoma, Non-Hodgkin |
Details
|
HOT-1030 |
HOT-1030 |
Phase 1 Clinical |
|
Solid tumours |
Details
|
QL-1806 |
QL-1806 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Neoplasms |
Details
|
Cedarizumab |
|
Phase 1 Clinical |
Therawisdom Biopharma Co Ltd |
Solid tumours; Carcinoma, Transitional Cell; Melanoma |
Details
|
Evunzekibart |
ATOR-1017 |
Phase 1 Clinical |
Alligator Bioscience Ab |
Solid tumours; Neoplasms |
Details
|